Current and historical daily PE Ratio for ICPT (
Intercept Pharmaceuticals Inc
) from 2012 to Jun 04 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Intercept Pharmaceuticals stock (ICPT) PE ratio as of Jun 04 2023 is 1.77.
More Details
Intercept Pharmaceuticals Inc (ICPT) PE Ratio (TTM) Chart
Intercept Pharmaceuticals Inc (ICPT) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1242
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Intercept Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-06-05 | 1.8 | 2023-03-30 | 2.1 |
| 2023-06-02 | 1.8 | 2023-03-29 | 2.2 |
| 2023-06-01 | 1.7 | 2023-03-28 | 2.2 |
| 2023-05-31 | 1.7 | 2023-03-27 | 2.1 |
| 2023-05-30 | 1.7 | 2023-03-24 | 2.1 |
| 2023-05-26 | 1.6 | 2023-03-23 | 2.1 |
| 2023-05-25 | 1.6 | 2023-03-22 | 2.1 |
| 2023-05-24 | 1.5 | 2023-03-21 | 2.2 |
| 2023-05-23 | 1.5 | 2023-03-20 | 2.3 |
| 2023-05-22 | 1.5 | 2023-03-17 | 2.4 |
| 2023-05-19 | 2.2 | 2023-03-16 | 2.4 |
| 2023-05-18 | 2.2 | 2023-03-15 | 2.4 |
| 2023-05-17 | 2.2 | 2023-03-14 | 2.4 |
| 2023-05-16 | 2.6 | 2023-03-13 | 2.5 |
| 2023-05-15 | 2.6 | 2023-03-10 | 2.5 |
| 2023-05-12 | 2.5 | 2023-03-09 | 2.9 |
| 2023-05-11 | 2.5 | 2023-03-08 | 3.0 |
| 2023-05-10 | 2.5 | 2023-03-07 | 3.1 |
| 2023-05-09 | 2.5 | 2023-03-06 | 3.2 |
| 2023-05-08 | 2.5 | 2023-03-03 | 3.2 |
| 2023-05-05 | 2.6 | 2023-03-02 | 3.2 |
| 2023-05-04 | 2.5 | 2023-03-01 | 3.1 |
| 2023-05-03 | 2.6 | 2023-02-28 | 3.1 |
| 2023-05-02 | 2.5 | 2023-02-27 | 3.1 |
| 2023-05-01 | 2.7 | 2023-02-24 | 3.0 |
| 2023-04-28 | 2.8 | 2023-02-23 | 3.0 |
| 2023-04-27 | 2.5 | 2023-02-22 | 3.0 |
| 2023-04-26 | 2.9 | 2023-02-21 | 3.0 |
| 2023-04-25 | 2.9 | 2023-02-17 | 3.1 |
| 2023-04-24 | 3.0 | 2023-02-16 | 3.0 |
| 2023-04-21 | 3.0 | 2023-02-15 | 3.2 |
| 2023-04-20 | 3.0 | 2023-02-14 | 3.3 |
| 2023-04-19 | 3.0 | 2023-02-13 | 3.2 |
| 2023-04-18 | 3.1 | 2023-02-10 | 3.2 |
| 2023-04-17 | 2.9 | 2023-02-09 | 3.2 |
| 2023-04-14 | 2.8 | 2023-02-08 | 3.2 |
| 2023-04-13 | 2.7 | 2023-02-07 | 3.4 |
| 2023-04-12 | 2.6 | 2023-02-06 | 3.2 |
| 2023-04-11 | 2.5 | 2023-02-03 | 2.9 |
| 2023-04-10 | 2.4 | 2023-02-02 | 3.0 |
| 2023-04-06 | 2.1 | 2023-02-01 | 2.9 |
| 2023-04-05 | 2.1 | 2023-01-31 | 2.8 |
| 2023-04-04 | 2.1 | 2023-01-30 | 2.8 |
| 2023-04-03 | 2.2 | 2023-01-27 | 2.8 |
| 2023-03-31 | 2.1 | 2023-01-26 | 2.8 |
Intercept Pharmaceuticals Inc (ICPT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Intercept Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US45845P1084
Compare
Compare
Traded in other countries / regions
I4P.GermanyICPT.MexicoICPT.USA IPO Date
2012-10-11Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers